Emerging role of long non-coding RNA JPX in malignant processes and potential applications in cancers

Long non-coding RNAs (lncRNAs) reportedly function as important modulators of gene regulation and malignant processes in the development of human cancers. The lncRNA JPX is a novel molecular switch for X chromosome inactivation and differentially expressed JPX has exhibited certain clinical correlations in several cancers. Notably, JPX participates in cancer growth, metastasis, and chemoresistance, by acting as a competing endogenous RNA for microRNA, interacting with proteins, and regulating some specific signaling pathways. Moreover, JPX may serve as a potential biomarker and therapeutic target for the diagnosis, prognosis, and treatment of cancer. The present article summarizes our current understanding of the structure, expression, and function of JPX in malignant cancer processes and discusses its molecular mechanisms and potential applications in cancer biology and medicine.

Automated summary

Long non-coding RNAs (lncRNAs) are crucial regulators of gene regulation and malignant processes in human cancers. The lncRNA JPX acts as a novel molecular switch for X chromosome inactivation and its differential expression has clinical correlations in various cancers. JPX is involved in cancer growth, metastasis, and chemoresistance through its role as a competing endogenous RNA, protein interaction, and regulation of specific signaling pathways. Furthermore, JPX has potential applications as a biomarker and therapeutic target in cancer diagnosis, prognosis, and treatment. This article provides a comprehensive summary of the structure, expression, and function of JPX in malignant cancer processes, and discusses its molecular mechanisms and potential applications in cancer biology and medicine.